Trending News Today: FDA, COTA Partner to Gain Insight into Cancer Treatment Variation

The FDA is partnering with COTA, a precision medicine technology company, to gain better insight into treatment variation within subpopulations of patients with cancer using real-world data, The American Journal of Managed Care reported. According to the article, the program will start with breast cancer and may expand to other cancer types. The evidence generated will be enriched with COPA’s patient classification system to better understand the variance of treatment and outcomes, the article reported.
 
Online pharmacy Valisure reported that it identified a new cancer-causing impurity in the blood pressure drug valsartan, Reuters reported. According to the article, Valisure informed the FDA in a citizen petition last week that it found through its own testing an impurity called dimethylformamide in some batches of the drug. The agency said it would review the petition but noted that the amount in the drugs was well below levels deemed to be potentially harmful, the article reported.
 
A new long-term analysis found that both infliximab (IFX) and golimumab (GLM) are effective at safely reducing ankylosing spondylitis (AS) symptoms, MD Magazine reported. According to the article, the study included 810 patients with AS who received either IFX or GLM. Overall, both IFX and GLM were well tolerated by patients with AS, significantly reduced disease activity, and improved functionality, the article reported.
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

A novel potential biomarker test could identify patients who would benefit from more advanced lung cancer screening.
Top news of the day from across the health care landscape.
In addition to a natural variation in genetic makeup, approximately 1 in 1000 people inherit a damaged or mutated copy of the BRCA1 gene from a parent.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$